NYSE$COR
Cencora Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Cencora reported Q2 fiscal 2025 revenue of $68.5B with net income of $717M and diluted EPS of $3.68.
Revenue reached $68.5 billion in the pharmaceutical distribution quarter as specialty and global segments grew. Net income was $717.4 million, or $3.68 per diluted share, with working-capital and generic pricing dynamics highlighted in MD&A.
- Q2 revenue $68.5B.
- Net income $717M; diluted EPS $3.68.
- Specialty distribution and global sourcing scale.
- Working capital and opioid litigation reserves monitored.
Headline financials
Revenue & EPS history
Cencora · Revenue · Quarterly
$75.5B
Forward guidance
Management discusses operating priorities, capital allocation, and sector risks in the quarterly filing.
Tailwinds
- Headline results and segment trends anchor the quarter.
- Liquidity and balance-sheet capacity support operations.
- Strategic initiatives outlined in MD&A.
Headwinds
- Macro, rates, or input costs may pressure margins.
- One-time items affect year-over-year comparability.
- Execution risk on growth or restructuring plans.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2025
-0.1%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+1.4%
Avg return
30 days after
48%
35 / 73 earnings
Positive
+7.8%
Q2 2019
Best reaction
-18.4%
Q2 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -18.4% | -16.6% | -10.1% | |
| Q1 2026 | -5.9% | +0.4% | -0.9% | |
| Q4 2025 | +2.9% | +5.8% | -1.4% | |
| Q3 2025 | -2.9% | -0.6% | +0.1% | |
| Q2 2025 | +4.6% | -4.3% | -0.6% | |
| Q1 2025 | +0.7% | -2.1% | +1.2% | |
| Q4 2024 | +5.9% | +6.5% | +4.0% | |
| Q3 2024 | +5.8% | +4.4% | +3.7% | |
| Q2 2024 | -6.0% | -6.3% | -5.2% | |
| Q1 2024 | +7.4% | +6.2% | +7.5% | |
| Q4 2023 | +4.2% | +4.7% | +9.0% | |
| Q3 2023 | +1.2% | -1.3% | -7.5% | |
| Q2 2023 | +0.1% | +0.7% | +3.5% | |
| Q1 2023 | -6.2% | -8.6% | -7.6% | |
| Q4 2022 | +4.4% | +3.1% | +12.4% | |
| Q3 2022 | -2.5% | -1.5% | +3.4% | |
| Q2 2022 | +2.9% | +4.4% | -2.5% | |
| Q1 2022 | +0.2% | +1.3% | +7.0% | |
| Q4 2021 | -0.6% | -2.8% | -9.0% | |
| Q3 2021 | -1.5% | -2.8% | +1.2% | |
| Q2 2021 | -6.5% | -2.1% | -7.1% | |
| Q1 2021 | +3.9% | +1.8% | -0.7% | |
| Q4 2020 | -1.0% | +4.8% | -1.9% | |
| Q3 2020 | -3.0% | -1.6% | -7.7% | |
| Q2 2020 | +3.0% | +3.6% | +15.8% | |
| Q1 2020 | -4.8% | -2.0% | -6.2% | |
| Q4 2019 | +1.6% | +1.0% | +4.2% | |
| Q3 2019 | +3.8% | -3.5% | -5.6% | |
| Q2 2019 | +7.8% | +5.5% | +6.1% | |
| Q1 2019 | +6.7% | +9.2% | +5.7% | |
| Q4 2018 | -2.3% | +0.3% | -2.9% | |
| Q3 2018 | +1.9% | +5.0% | +13.2% | |
| Q2 2018 | -4.3% | -5.1% | -6.6% | |
| Q1 2018 | +2.5% | -2.9% | +4.7% | |
| Q4 2017 | -2.4% | -2.2% | +10.9% | |
| Q3 2017 | -11.4% | -12.0% | -12.1% | |
| Q2 2017 | +3.9% | +5.9% | +13.2% | |
| Q1 2017 | +6.0% | +6.8% | +9.9% | |
| Q4 2016 | +3.6% | +3.1% | +12.9% | |
| Q3 2016 | +5.1% | +4.5% | +1.9% | |
| Q2 2016 | -9.2% | — | — | |
| Q1 2016 | -3.7% | — | — | |
| Q4 2015 | -1.0% | — | — | |
| Q3 2015 | -5.4% | — | — | |
| Q2 2015 | +1.9% | — | — | |
| Q1 2015 | +0.4% | — | — | |
| Q4 2014 | +7.1% | — | — | |
| Q3 2014 | +3.7% | — | — | |
| Q2 2014 | -3.1% | — | — | |
| Q1 2014 | -4.3% | — | — | |
| Q4 2013 | +1.8% | — | — | |
| Q3 2013 | -0.0% | — | — | |
| Q2 2013 | -4.6% | — | — | |
| Q1 2013 | -5.1% | — | — | |
| Q4 2012 | -0.6% | — | — | |
| Q3 2012 | +2.7% | — | — | |
| Q2 2012 | -1.2% | — | — | |
| Q1 2012 | +2.4% | — | — | |
| Q4 2011 | -1.0% | — | — | |
| Q3 2011 | -0.5% | — | — | |
| Q2 2011 | +2.9% | — | — | |
| Q1 2011 | +0.5% | — | — | |
| Q4 2010 | -0.5% | — | — | |
| Q3 2010 | -0.7% | — | — | |
| Q2 2010 | +1.0% | — | — | |
| Q1 2009 | -1.7% | — | — | |
| Q1 2010 | +1.2% | — | — | |
| Q4 2009 | -0.6% | — | — | |
| Q2 2009 | -0.6% | — | — | |
| Q4 2007 | -0.6% | — | — | |
| Q3 2008 | -0.5% | — | — | |
| Q3 2009 | -0.5% | — | — | |
| Q4 2008 | -0.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro